CLEO Diagnostics Ltd

As of June 30, 2026, CLEO Diagnostics Ltd carries a market capitalization of 68.56M, placing it among publicly traded companies globally. Its enterprise value stands at 62.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CLEO Diagnostics Ltd has 137.11M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CLEO Diagnostics Ltd maintains a current ratio of 3.80, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CLEO Diagnostics Ltd posted a negative return on equity (ROE) of -109.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -87.19, reflecting losses generated across the asset base.

As of the close on October 22, 2026, CLEO Diagnostics Ltd's stock has declined approximately 22.78% over the past 52 weeks. The 50-day moving average sits at 0.33, while the 200-day moving average is 0.49.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -7.82M, while operating income came in at -7.89M.

These figures are as of June 30, 2026. Total book value stands at 5.01M, with working capital of 4.67M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -6.87, meaning CLEO Diagnostics Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.